UK markets closed

Biogen Inc. (BIIB.MX)

Mexico - Mexico Delayed price. Currency in MXN
Add to watchlist
3,902.080.00 (0.00%)
At close: 10:44AM CDT
Sign in to post a message.
  • R
    RNB
    Was the after hours trade at $200 due to options being exercised after hour?

    What was the volume of trading after hours on May 27, 2022?
  • D
    DigitalRobberBarons
    I'm mostly cash but hanging out in these beat up pharma names. If they pop I'll take some off the table, but I'm sure people still have to buy drugs during inflation, deflation, recession, etc... I think consolidation is still going to happen in this industry and BIIB is at a value that makes them a target.
  • G
    Guy
    this knife Is probably on the floor so I'm buying 250 shares at this price and more if at a later date if it gets pushed down with the market. I've traded it before so these shares are free from the last run. when this stock runs 🏃‍♂️next it will jump big
  • d
    demetrios
    This stock market cap is only 30 billion. I don’t think it will last long as independent. Any good news about Alzheimer’s and it is a double and triple
  • T
    Turbopicks
    (BIVI) MC 71 m...3x Blockbusters in Pipeline targeting Alzheimer Disease (Phase 3 data in mid 2023) and Parkinsons Disease (Phase 2 data coming this quarter) (Slide Presentation below)=10 Bagger opp
    https://bioviepharma.com/wp-content/uploads/2022/04/BioVie-Company-Overview-2022-04-13.pdf

    #+#+
  • d
    demetrios
    Pfizer bought a nothing company for 12 billion. Biogen is definitely a target.
  • P
    Puff Pastry
    Biogen giving up on its Alzheimer’s drug was a smart move for the company. They will likely look to buying a company like Cassava Sciences that has the holy grail of Alzheimer’s drugs ..
  • d
    demetrios
    There is speculation that merck might be interested in acquiring biogen. Now that the CEO is leaving, that might become a reality
  • d
    demetrios
    If an Alzheimer’s treatment get full approval this is a 500 dollar stock
  • U
    Umer
    I think its a very wise move by Biogen to stop and limit the damage caused by its Alzheimer’s drug and instead consider partnering with the best in class business Sava for its Alzheimers drug in phase 3 trials that should help put the company back to potential hyper growth territory. Biogen could use its strong leverage with regulatory authorities to gain fast track approval and commercialization GLTA
  • d
    demetrios
    If biogen is sold now that the CEO is gone it would fetch 300 dollars a share. Market cap now is a cheap 28 billion.
  • S
    SamIAm
    Only reason this could possibly move up is on news ceo is leaving. Pretty sad!
  • d
    demetrios
    Good price action for biogen after the removal of the CEO. A lot of people believe that this might be a preparation for selling the company. Market cap only 30 billion. If it is acquired it would go for at least 280 to 300 dollars a share.
  • s
    scorp
    Everyone forget Aduhelm! Focus on the 2nd drug they have and let’s hope they don’t mess that up with the pricing . If it’s priced at 19k a year there will takers worldwide.

    There is no reason for the FDA not to pass this one fast track after Aduhelm . Clearly they will present better data this time or else not file at all.
  • J
    John Abraham
    I am scared of them losing market share. Wait for $100.
  • B
    Burrill
    Investors should look at SAVA.
  • I
    IrvingT
    Super cheap. Market cap only 30 billion dollars. Could double in no time
  • B
    BFF
    don't blame biogen for getting into this debacle and mess. you can blame the FDA. this drug should have NEVER been approved in the first place.
  • S
    Singer
    So all M+A is on hold waiting for new CEO? AUPH hoping BIIB would make a bid!!!
  • Y
    Yahoo Finance Insights
    Biogen reached a 52 Week low at 188.57